Taking aspirin regularly for long periods significantly reduce the risk of colorectal cancer, shows the analysis of two large study released Thursday that confirm the anticancer properties of this anti-inflammatory.
“We can now recommend to many people consider taking aspirin to reduce their risk of colorectal cancer” said Dr. Andrew Chan, head of the clinical epidemiology unit at Massachusetts General hospital (MGH), a lead author of the study.
However, he stressed “at this stage, we are not able to make a general recommendation for the use of aspirin for the prevention of all forms of cancer.”
the researchers analyzed medical data nearly 136,000 participants, men and women, on a 32-year period. The results show that those who say they regularly absorb aspirin, namely a standard dose (300 mg) or low (80 mg) at least twice a week, reduce by 19% their risk of colorectal cancer and 15% that of all forms of gastrointestinal tumors compared to those failing to take regularly.
experts, however, warn against the potential bleeding risks of aspirin.